Bisphosphonate Lipid LNPs for Bone-Targeted RNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current delivery systems for therapeutics to the bone microenvironment face challenges due to low delivery efficiency and high toxicity, necessitating high dosing and increased side effects, particularly for RNA therapeutics like mRNA and gene editing technologies.
Innovation Solution
Development of bisphosphonate lipid nanoparticles (LNPs) with specific components such as bisphosphonate lipids, neutral phospholipids, cholesterol lipids, and polymer-conjugated lipids, designed for targeted delivery to the bone microenvironment, enhancing delivery efficacy and reducing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional delivery systems (organic/inorganic nanocomposites, hydrogels) are used for therapeutic delivery to bone, then some delivery capability is achieved, but delivery efficiency is low and toxicity is high
Solution Approach 1:
The patent employs composite lipid structures combining bisphosphonate moieties with lipid tails to create LNPs that simultaneously achieve bone targeting and efficient RNA delivery. This composite approach resolves the contradiction by integrating the bone-binding capability of bisphosphonates with the membrane-permeable properties of lipids, achieving high delivery efficiency without the toxicity associated with conventional nanocomposites and hydrogels.
Solution Approach 2:
The patent modifies the chemical parameters of lipid molecules by incorporating bisphosphonate groups at specific positions (e.g., C1, C2, C3 of the lipid chain) to change the affinity and binding characteristics of the LNP for bone minerals. This parameter change enables selective accumulation at bone sites, improving delivery efficiency while maintaining biocompatibility and reducing toxicity.
2Reliability
If high dosing is used to achieve ideal therapeutic dosage at diseased sites, then therapeutic efficacy is improved, but side effects increase
Solution Approach 1:
The patent creates local quality differentiation by designing LNPs with bisphosphonate groups that specifically bind to hydroxyapatite crystals in bone, enabling localized delivery of RNA therapeutics to bone sites. This local targeting approach ensures high therapeutic efficacy at the disease site while minimizing systemic distribution and associated side effects, eliminating the need for high dosing.
Solution Approach 2:
The LNP serves as an intermediary carrier that facilitates targeted delivery of RNA therapeutics to bone cells. The bisphosphonate-lipid composite structure acts as a mediator between the therapeutic agent and the bone microenvironment, enabling efficient uptake by osteoblasts and other bone cells while avoiding non-specific tissue interaction and side effects.
3Productivity
If conventional materials are used for targeted delivery, then some targeting capability is achieved, but delivery efficacy remains insufficient
Solution Approach 1:
The patent segments the LNP structure into distinct functional components: bisphosphonate moieties for bone binding, lipid tails for membrane integration, and encapsulated RNA therapeutics for biological activity. This segmentation allows each component to optimize its specific function, achieving superior delivery efficacy and bioavailability compared to conventional non-segmented delivery systems.
Data Source
AI summary
Described herein, in some aspects, are bisphosphonate lipid compounds, lipid nanoparticles (LNPs) thereof, and methods of use thereof. In various embodiments, the LNP selectively targets a cell of interest (e.g., a bone cell and/or bone marrow cell, such as a stem cell, stroma cell, osteoblast, osteocyte, osteoclast, bone lining cell, local mesenchymal cell, progenitor cell, mononuclear blood-borne precursor cell, B cell, endothelial cell, granulocytes, T cell, monocytic lineage, B cell lineage, monocytes, cancer cell, tumor cell, tumor cell that metastasizes to bone, blood cancer cell, and multiple myeloma cell, inter alia). In other aspects, the present disclosure relates to methods for in vivo delivery of therapeutic agents to prevent or treat diseases, disorders, or conditions using the LNP compositions of the disclosure.